KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Non-Current Receivables (2016 - 2026)

Gsk has reported Non-Current Receivables over the past 18 years, most recently at $10.5 billion for Q1 2026.

  • For Q1 2026, Non-Current Receivables rose 17.61% year-over-year to $10.5 billion; the TTM value through Mar 2026 reached $10.5 billion, up 17.61%, while the annual FY2025 figure was $9.9 billion, 13.26% up from the prior year.
  • Non-Current Receivables for Q1 2026 was $10.5 billion at Gsk, up from $9.9 billion in the prior quarter.
  • Over five years, Non-Current Receivables peaked at $10.8 billion in Q3 2023 and troughed at $3.2 billion in Q1 2022.
  • A 5-year average of $8.9 billion and a median of $8.9 billion in 2025 define the central range for Non-Current Receivables.
  • Biggest five-year swings in Non-Current Receivables: plummeted 63.8% in 2022 and later soared 156.3% in 2023.
  • Year by year, Non-Current Receivables stood at $8.3 billion in 2022, then grew by 10.8% to $9.2 billion in 2023, then decreased by 4.28% to $8.8 billion in 2024, then increased by 13.26% to $9.9 billion in 2025, then grew by 5.22% to $10.5 billion in 2026.
  • Business Quant data shows Non-Current Receivables for GSK at $10.5 billion in Q1 2026, $9.9 billion in Q4 2025, and $10.7 billion in Q3 2025.